Furthermore, macrophage infiltration into human glioblastomas, resistant to anti-VEGF therapy, is correlated with a poor prognosis, but a combinatorial therapy with anti-VEGF and anti-ANG2 (angiopoietin-2) was shown to reprogram TAMs from M2 into M1 phenotype with relevant anti-tumor activity (217). This evidence concerns the gene VEGFA and glioblastoma.